Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective.

Allo-HSCT remains one of the curable therapies for ALL in the era of targeted therapy and immunotherapy. Future directions should focus on decreasing relapse mortality and nonrelapse mortality to further improve the outcomes of patients with ALL.